Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENECA: RT/SBRT + Chemotherapy in Metastatic Pancreatic Cancer
NCT06946420Phase 3Active, not recruiting
- Sponsor
- Policlinico Gemelli
- Start
- Jan 2025
- Primary completion
- Jan 2030
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Policlinico Gemelli. Primary endpoint: Absence of symptoms at 12 months. Started Jan 2025; status: active, not recruiting.
Beyond the preview
Go deeper on NCT06946420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06946420.